Files

668396.pdf (204.4 KB)

Document type

Article

Version

Published version

Publication date

2017-02

Publication license

cc-by-nc (c) Darbà, Josep et al., 2017
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/107750

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax compared with Turbuhaler in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.2147/CEOR.S125301

Abstract

The objective of this study was to estimate the economic impact of the introduction of DuoResp® Spiromax®, budesonide/formoterol fixed-dose combination (FDC), focusing on an increase in medication adherence due to an enhancement of the inhalation technique for the treatment of COPD patients in Spain and 5 regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. ...

Subject

Administració de medicaments, Malalties pulmonars obstructives cròniques, Tractament tèrmic, Economia de la salut

Subject (English)

Administration of drugs, Chronic obstructive pulmonary diseases, Heat treatment, Medical economics

Citation

Collections

Articles publicats en revistes (Economia)

Citation

DARBÀ, Josep, et al. Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax compared with Turbuhaler in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain. Clinicoeconomics and Outcomes Research. 2017. Vol. 9, num. February, pags. 127-137. ISSN 1178-6981. [consulted: 8 of June of 2026]. Available at: https://hdl.handle.net/2445/107750

Export metadata

JSON - METS

Share record